Ignite Creation Date:
2025-12-24 @ 11:13 PM
Ignite Modification Date:
2025-12-25 @ 8:49 PM
Study NCT ID:
NCT06323369
Status:
RECRUITING
Last Update Posted:
2024-05-17
First Post:
2024-03-15
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Clinically Node-negative Head and Neck Squamous Cell Carcinoma
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000077195', 'term': 'Squamous Cell Carcinoma of Head and Neck'}], 'ancestors': [{'id': 'D002294', 'term': 'Carcinoma, Squamous Cell'}, {'id': 'D002277', 'term': 'Carcinoma'}, {'id': 'D009375', 'term': 'Neoplasms, Glandular and Epithelial'}, {'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D006258', 'term': 'Head and Neck Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D011827', 'term': 'Radiation'}], 'ancestors': [{'id': 'D055585', 'term': 'Physical Phenomena'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'PREVENTION', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 154}}, 'statusModule': {'overallStatus': 'RECRUITING', 'startDateStruct': {'date': '2024-03-25', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2024-05', 'completionDateStruct': {'date': '2029-09-25', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2024-05-16', 'studyFirstSubmitDate': '2024-03-15', 'studyFirstSubmitQcDate': '2024-03-15', 'lastUpdatePostDateStruct': {'date': '2024-05-17', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2024-03-21', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2029-03-25', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Disease-Free Survival(DFS )', 'timeFrame': '3years', 'description': 'Time from randomization until recurrence of tumor or death from any cause'}, {'measure': 'Lymph node positivity rate', 'timeFrame': 'Within 30 days after surgery', 'description': 'Proportion of positive lymph nodes in resection specimens among total subjects'}], 'secondaryOutcomes': [{'measure': 'Percentage of Participants Who Experienced High-Grade (Grade 3-4 and Grade 5) Adverse Events', 'timeFrame': 'From time of first dose of study treatment until the end of follow-up (up to 5 years)', 'description': 'High-grade adverse events were tabulated using worst grade per Common Terminology Criteria for Adverse Events, National Cancer Institute (NCI CTCAE) Version 5.0 criteria.'}, {'measure': 'Pathological complete response (pCR) rate', 'timeFrame': 'Up to 30 days post-sugery', 'description': 'pCR is defined as the absence of invasive squamous cell carcinoma within the resected primary tumor specimen and all the sampled regional lymph nodes.'}, {'measure': 'Major Pathological Response (MPR) rate', 'timeFrame': 'Up to 30 days post-sugery', 'description': 'MPR is defined as ≤10% invasive squamous cell carcinoma within the resected primary tumor specimen and all the sampled regional lymph nodes'}, {'measure': 'lymph node division', 'timeFrame': 'Within 30 days after surgery', 'description': 'Lymph node division in patients with lymph node metastasis'}, {'measure': 'Event-free Survival (EFS)', 'timeFrame': '3 years', 'description': 'EFS is the time from the date of randomization to the date of first record of any of the following events: disease progression; local or distant recurrence as assessed with imaging or biopsy as indicated; or death due to any cause.'}, {'measure': 'Overall survival (OS)', 'timeFrame': '1years,2years,3years,5years', 'description': "Time from randomization to subject's death from any cause"}, {'measure': 'Disease-Free Survival(DFS )', 'timeFrame': '1years,2years,5years', 'description': 'Time from randomization until recurrence of tumor or death from any cause'}]}, 'oversightModule': {'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Head and Neck Squamous Cell Carcinoma']}, 'descriptionModule': {'briefSummary': 'A prospective, randomized, open-label, multicenter Phase 2 trial designed to compare the efficacy and safety of Tislelizumab combined with chemotherapy followed by surgery versus up-front surgery in resectable clinically node-negative head and neck squamous cell carcinoma.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '75 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\nHave a histologically confirmed diagnosis of HNSCC which is planned for treatment with curative intent including surgical resection: stage III/IVA.\n\nGreater than or equal to 18 and less than 80 years of age at time of study entry.\n\nECOG performance status of 0 or 1. Measurable disease as per RECIST 1.1. Patients must have no prior exposure to immune-mediated therapy, including anti- cytotoxic T-lymphocyte protein 4 (CTLA-4), anti-programmed cell death 1, anti-programmed cell death 1 ligand 1 (PD-L1), or anti-programmed cell death ligand 2 antibodies, excluding therapeutic anticancer vaccines.\n\nScreening labs must meet the following criteria and must be obtained within 14 days prior to registration:\n\nAdequate hepatic and renal function as demonstrated by\n\nSerum creatinine \\< 1.5 X ULN or CrCl \\> 40mL/min (if using the Cockcroft-Gault formula below):\n\nMales: Creatinine CL (mL/min) = (Weight (kg) x (140 - Age))/(72 x serum creatinine (mg/dL)） Females: Creatinine CL (mL/min) = (Weight (kg) x (140 - Age))/(72 x serum creatinine (mg/dL))x 0.85 AST/ALT ≤ 3 x ULN Total Bilirubin ≤ 1.5 x ULN (except subjects with Gilbert Syndrome, who can have total bilirubin \\< 3.0 mg/dL)\n\nAdequate bone marrow function as demonstrated by:\n\nAbsolute Neutrophil Count \\>1,500/µL Platelets \\> 100 X 103/µL Hemoglobin \\> 9.0 g/dL Women of reproductive potential should have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin \\[HCG\\]) within 21 days of study enrollment.\n\nWomen of reproductive potential must use highly effective contraception methods to avoid pregnancy for 23 weeks after the last dose of study drugs; "women of reproductive potential" is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal; menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes; in addition, women under the age of 55 must have a documented serum follicle stimulating hormone (FSH) level less than 40 mIU/mL.\n\nMen of reproductive potential who are sexually active with women of reproductive potential must use any contraceptive method with a failure rate of less than 1% per year; men who are receiving the study medications will be instructed to adhere to contraception for 31 weeks after the last dose of study drugs; men who are azoospermic do not require contraception.\n\nAbility to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).\n\nSubject is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.\n\nSubjects must agree to allow use of any pre-treatment tissue remaining after definitive diagnosis is made (ie, archival and or fresh tissue) for research purposes. In addition, subjects must consent to allow use of their residual post-operative tissue for research purposes.\n\nExclusion Criteria:\n\nIs currently participating in or has participated in a study of an investigational agent within 4 weeks of the first dose of treatment or has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier.\n\nHas had another known invasive malignancy within the previous 5 years and/or has had surgery, chemotherapy, targeted small molecule therapy or radiation therapy within 5 years for a known malignancy prior to study day 0.\n\nIf subject received major surgery for any other reason, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.\n\nSubjects with a condition requiring systemic treatment with either corticosteroids (\\> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of day -5. Inhaled or topical steroids, and adrenal replacement steroid \\> 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.\n\nHas an active autoimmune disease requiring systemic steroid treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids.\n\nActive, known or suspected autoimmune disease. Note: Subjects are permitted to enroll if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger .\n\nHas evidence of interstitial lung disease or active, non-infectious pneumonitis.\n\nHas an active infection requiring systemic therapy. Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell costimulation or immune checkpoint pathways.\n\nA history of allergic reaction attributed to compounds of similar chemical or biologic composition to the treatment or other agents used in the study.\n\nHas a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject\'s participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.\n\nHas known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n\nIs pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 23 weeks after the last dose of trial treatment.\n\nHas a known history of Human Immunodeficiency Virus (HIV) infection (HIV 1/2 antibodies).\n\nHas known active Hepatitis B or C. Known history of active TB (bacillus tuberculosis ).'}, 'identificationModule': {'nctId': 'NCT06323369', 'briefTitle': 'Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Clinically Node-negative Head and Neck Squamous Cell Carcinoma', 'organization': {'class': 'OTHER', 'fullName': 'Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University'}, 'officialTitle': 'Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Clinically Node-negative Head and Neck Squamous Cell Carcinoma', 'orgStudyIdInfo': {'id': 'SYSKY-2023-1283-02'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Neoadjuvant Tislelizumab + Chemotherapy (Arm A)', 'description': 'Neoadjuvant therapy ( 3 cycles ) ： Cycle1、2、3（Cycle length: 21 days）：Tislelizumab(IV) , dose= 200mg, day=1; Cisplatin(IV) , dose=75 mg/m2, or Carboplatin(IV) , AUC=5, day=1; Nab-paclitaxel (IV), dose=260mg/m2, day=1.\n\nFollowing surgical resection, lymph node positive participants receive 200 mg Tislelizumab Q3W plus chemoradiotherapy as adjuvant therapy. Lymph node negative participants receive 200 mg Tislelizumab Q3W as adjuvant therapy.', 'interventionNames': ['Drug: Tislelizumab（neoadjuvant）', 'Drug: Cisplatin （neoadjuvant）', 'Drug: Nab-paclitaxel （neoadjuvant）', 'Procedure: Surgical resection', 'Drug: Cisplatin（adjuvant）', 'Drug: Tislelizumab（adjuvant）', 'Radiation: Radiation', 'Drug: Carboplatin（neoadjuvant）', 'Drug: Carboplatin（adjuvant）']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Up-front Surgery (Arm B)', 'description': 'Following surgical resection, lymph node positive participants receive chemoradiotherapy as adjuvant therapy. Lymph node negative participants receive follow-up.', 'interventionNames': ['Procedure: Surgical resection', 'Drug: Cisplatin（adjuvant）', 'Radiation: Radiation', 'Drug: Carboplatin（adjuvant）']}], 'interventions': [{'name': 'Tislelizumab（neoadjuvant）', 'type': 'DRUG', 'description': 'Tislelizumab 200 mg administered by intravenous (IV) infusion on Day 1 of each 21-day cycle', 'armGroupLabels': ['Neoadjuvant Tislelizumab + Chemotherapy (Arm A)']}, {'name': 'Cisplatin （neoadjuvant）', 'type': 'DRUG', 'description': 'Cisplatin 75 mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle', 'armGroupLabels': ['Neoadjuvant Tislelizumab + Chemotherapy (Arm A)']}, {'name': 'Nab-paclitaxel （neoadjuvant）', 'type': 'DRUG', 'description': 'Nab-paclitaxel 260mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle', 'armGroupLabels': ['Neoadjuvant Tislelizumab + Chemotherapy (Arm A)']}, {'name': 'Surgical resection', 'type': 'PROCEDURE', 'description': 'Standard of care', 'armGroupLabels': ['Neoadjuvant Tislelizumab + Chemotherapy (Arm A)', 'Up-front Surgery (Arm B)']}, {'name': 'Cisplatin（adjuvant）', 'type': 'DRUG', 'description': 'Cisplatin 100 mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle', 'armGroupLabels': ['Neoadjuvant Tislelizumab + Chemotherapy (Arm A)', 'Up-front Surgery (Arm B)']}, {'name': 'Tislelizumab（adjuvant）', 'type': 'DRUG', 'description': 'Tislelizumab 200 mg administered by intravenous (IV) infusion on Day 1 of each 21-day cycle', 'armGroupLabels': ['Neoadjuvant Tislelizumab + Chemotherapy (Arm A)']}, {'name': 'Radiation', 'type': 'RADIATION', 'description': 'Recommended, standard of care', 'armGroupLabels': ['Neoadjuvant Tislelizumab + Chemotherapy (Arm A)', 'Up-front Surgery (Arm B)']}, {'name': 'Carboplatin（neoadjuvant）', 'type': 'DRUG', 'description': 'Cisplatin AUC=5 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle', 'armGroupLabels': ['Neoadjuvant Tislelizumab + Chemotherapy (Arm A)']}, {'name': 'Carboplatin（adjuvant）', 'type': 'DRUG', 'description': 'Cisplatin AUC=5 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle', 'armGroupLabels': ['Neoadjuvant Tislelizumab + Chemotherapy (Arm A)', 'Up-front Surgery (Arm B)']}]}, 'contactsLocationsModule': {'locations': [{'zip': '510120', 'city': 'Guangzhou', 'state': 'Yuexiu', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'Song Fan, Doctor', 'role': 'CONTACT', 'email': 'fansong2@mail.sysu.edu.cn', 'phone': '13570536658', 'phoneExt': '+86'}, {'name': 'Song Fan, Doctor', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Medical Ethics Committee of Sun Yat-sen Memorial Hospital', 'geoPoint': {'lat': 23.11667, 'lon': 113.25}}], 'centralContacts': [{'name': 'Bin Wei', 'role': 'CONTACT', 'email': 'weib6@mail2.sysu.edu.cn', 'phone': '18476425874', 'phoneExt': '+86'}, {'name': 'Qunxing Li', 'role': 'CONTACT', 'email': 'liqx73@mail.sysu.edu.cn', 'phone': '81332471', 'phoneExt': '020'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'UNDECIDED'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University', 'class': 'OTHER'}, 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Associate Professor', 'investigatorFullName': 'Song Fan, MD', 'investigatorAffiliation': 'Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University'}}}}